Drug Approval | October 14, 2021
IOL receives Korean FDA approval
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The drug is being developed at lab scale for the first-line of treatment of Covid-19
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
This opens up a huge market for the company’s Magnezis implants in India
The company plans to expand its portfolio in regulated markets aggressively
Subscribe To Our Newsletter & Stay Updated
